HUP9900789A2 - Lefelé irányuló szabályozásra rezisztens C3 konvertáz - Google Patents

Lefelé irányuló szabályozásra rezisztens C3 konvertáz

Info

Publication number
HUP9900789A2
HUP9900789A2 HU9900789A HUP9900789A HUP9900789A2 HU P9900789 A2 HUP9900789 A2 HU P9900789A2 HU 9900789 A HU9900789 A HU 9900789A HU P9900789 A HUP9900789 A HU P9900789A HU P9900789 A2 HUP9900789 A2 HU P9900789A2
Authority
HU
Hungary
Prior art keywords
proteins
höman
native
stone
amino acid
Prior art date
Application number
HU9900789A
Other languages
English (en)
Inventor
Timothy Charles Farries
Richard Alexander Harrison
Original Assignee
Imutran Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604865.7A external-priority patent/GB9604865D0/en
Priority claimed from GBGB9611896.3A external-priority patent/GB9611896D0/en
Priority claimed from GBGB9614293.0A external-priority patent/GB9614293D0/en
Priority claimed from GBGB9624028.8A external-priority patent/GB9624028D0/en
Application filed by Imutran Limited filed Critical Imutran Limited
Publication of HUP9900789A2 publication Critical patent/HUP9900789A2/hu
Publication of HUP9900789A3 publication Critical patent/HUP9900789A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát lefelé irányűló szabályőzásra rezisztens C3kőnvertázők kialakítására képes módősítőtt fehérjék, ilyen fehérjéketkódőló DNS-szekvenciák, és ilyen fehérjéknek terápiás szerekként -elsősőrban beültetett idegen szervek kilökődésének gátlására - történőfelhasználása képezi. A módősítőtt fehérjék a natív hűmán C3 aminősavmaradékainak megfelelő egy vagy több aminősavmaradék cseréjével,deléciójával és inszerciójával létrehőzőtt műtációk következtében Hés/vagy I faktőrral, valamint CR1, MCP és/vagy DAF kőmplementgátlóaktivitásával szemben a natív hűmán C3-hőz képest csökkentérzékenységgel rendelkeznek. ŕ
HU9900789A 1996-03-07 1997-03-04 Down-regulation resistant c3 convertase HUP9900789A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9604865.7A GB9604865D0 (en) 1996-03-07 1996-03-07 Modified proteins
GBGB9611896.3A GB9611896D0 (en) 1996-06-07 1996-06-07 Modified proteins
GBGB9614293.0A GB9614293D0 (en) 1996-07-08 1996-07-08 Modified proteins
GBGB9624028.8A GB9624028D0 (en) 1996-11-19 1996-11-19 Modified proteins

Publications (2)

Publication Number Publication Date
HUP9900789A2 true HUP9900789A2 (hu) 1999-07-28
HUP9900789A3 HUP9900789A3 (en) 2001-10-29

Family

ID=27451421

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900789A HUP9900789A3 (en) 1996-03-07 1997-03-04 Down-regulation resistant c3 convertase

Country Status (18)

Country Link
US (2) US6268485B1 (hu)
EP (1) EP0885301A1 (hu)
JP (1) JP2000515001A (hu)
KR (1) KR19990087571A (hu)
CN (1) CN1227359C (hu)
AR (1) AR006150A1 (hu)
AU (1) AU726187B2 (hu)
BR (1) BR9708005A (hu)
CA (1) CA2247615A1 (hu)
CZ (1) CZ283598A3 (hu)
HU (1) HUP9900789A3 (hu)
IL (1) IL125862A0 (hu)
NO (1) NO984073L (hu)
NZ (1) NZ331595A (hu)
PL (1) PL328706A1 (hu)
SK (1) SK121798A3 (hu)
TR (1) TR199801769T2 (hu)
WO (1) WO1997032981A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US6998243B2 (en) * 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
EP2152736B1 (en) * 2007-05-03 2017-07-05 Lysomab GmbH Complement factor h-derived short consensus repeat-antibody constructs
CN101809034B (zh) * 2007-06-07 2015-07-08 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
RU2549468C2 (ru) * 2013-08-09 2015-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
JPH10505241A (ja) 1994-09-08 1998-05-26 イムトラン・リミテッド 改変タンパク質

Also Published As

Publication number Publication date
CN1214733A (zh) 1999-04-21
AU2225797A (en) 1997-09-22
TR199801769T2 (xx) 1998-11-23
AU726187B2 (en) 2000-11-02
CN1227359C (zh) 2005-11-16
KR19990087571A (ko) 1999-12-27
EP0885301A1 (en) 1998-12-23
NZ331595A (en) 2000-02-28
CZ283598A3 (cs) 1999-02-17
US20020068059A1 (en) 2002-06-06
BR9708005A (pt) 2000-01-04
PL328706A1 (en) 1999-02-15
SK121798A3 (en) 1999-04-13
WO1997032981A1 (en) 1997-09-12
NO984073D0 (no) 1998-09-04
US6268485B1 (en) 2001-07-31
IL125862A0 (en) 1999-04-11
CA2247615A1 (en) 1997-09-12
AR006150A1 (es) 1999-08-11
HUP9900789A3 (en) 2001-10-29
US7002001B2 (en) 2006-02-21
NO984073L (no) 1998-11-02
JP2000515001A (ja) 2000-11-14

Similar Documents

Publication Publication Date Title
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
HUP9902698A2 (hu) Humán bikunin
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
DE60213648D1 (de) Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln
LU93259I2 (fr) LETIFEND (Protein Q)
NZ515678A (en) Human GIL-19/AE289 proteins and polynucleotides encoding same
HUP9900789A2 (hu) Lefelé irányuló szabályozásra rezisztens C3 konvertáz
NZ508505A (en) Treatment of wounds using an Egr-1 transcription factor polypeptide
ATE287952T1 (de) Humanes thymosin beta 15 gen,protein und dessen verwendungen
ATE166656T1 (de) Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
BR0309921A (pt) Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ES2032812T3 (es) Vacuna.
NO20052525L (no) Spleisevariant av humant hypofyseveksthormon
DE69529235D1 (de) Menschliche dnase i varianten
DK1012286T3 (da) Allelvariant af humant STAT3
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1
ATE321143T1 (de) Genexpression in monocyten und makrophagen
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
MX9706429A (es) Variantes de dnasa i humana.
NO900745L (no) Humant mannose-bindende protein.